Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.
Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP. Khanna D, et al. Among authors: pope je. J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231. J Scleroderma Relat Disord. 2017. PMID: 28516167 Free PMC article.
A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE. Pope JE, et al. Arthritis Rheum. 2001 Jun;44(6):1351-8. doi: 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I. Arthritis Rheum. 2001. PMID: 11407694 Free article. Clinical Trial.
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Sultan N, Pope JE, Clements PJ; Scleroderma Trials Study Group. Sultan N, et al. Among authors: pope je. Rheumatology (Oxford). 2004 Apr;43(4):472-8. doi: 10.1093/rheumatology/keh070. Epub 2003 Dec 16. Rheumatology (Oxford). 2004. PMID: 14679295 Clinical Trial.
Office capillaroscopy in systemic sclerosis.
Baron M, Bell M, Bookman A, Buchignani M, Dunne J, Hudson M, Jerome D, Johnson SR, Jones N, Kaminska E, Lupton T, Mathieu JP, Pope J, Steele R, Taillefer S. Baron M, et al. Clin Rheumatol. 2007 Aug;26(8):1268-74. doi: 10.1007/s10067-006-0489-6. Epub 2006 Dec 9. Clin Rheumatol. 2007. PMID: 17160528 Clinical Trial.
The cost of systemic sclerosis.
Bernatsky S, Hudson M, Panopalis P, Clarke AE, Pope J, Leclercq S, St Pierre Y, Baron M; Canadian Scleroderma Research GroupAdditional members of the Canadian Scleroderma Research Group are shown in Appendix A. Bernatsky S, et al. Arthritis Rheum. 2009 Jan 15;61(1):119-23. doi: 10.1002/art.24086. Arthritis Rheum. 2009. PMID: 19116974 Free article.
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM. Chung L, et al. Arthritis Rheum. 2009 Mar;60(3):870-7. doi: 10.1002/art.24351. Arthritis Rheum. 2009. PMID: 19248104 Free article. Clinical Trial.
Digital ulcers: overt vascular disease in systemic sclerosis.
Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Steen V, et al. Among authors: pope je. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii19-24. doi: 10.1093/rheumatology/kep105. Rheumatology (Oxford). 2009. PMID: 19487218 Review.
489 results